Abstract Number: 889 • 2016 ACR/ARHP Annual Meeting
The Utility of Patient-Reported Outcomes in Predicting Disease Activity in Patients with Takayasu’s Arteritis
Background/Purpose: Takayasu’s arteritis (TAK) is a relapsing large vessel vasculitis. There are currently no reliable predictors of disease relapse. This study explored whether changes in…Abstract Number: 2018 • 2016 ACR/ARHP Annual Meeting
A Clinical Risk Prediction Model for Skin Thickness Progression in Early Diffuse Scleroderma
Background/Purpose: Systemic sclerosis (SSc) is a rapidly evolving field with multiple potential therapeutic agents under development and several active clinical trials focused on treating…Abstract Number: 2430 • 2015 ACR/ARHP Annual Meeting
Immunological Risk Factors after Rituximab Therapy in Patients with Pediatric Rheumatic Diseases – a Prospective Single-Center Study
Background/Purpose: Rituximab (RTX) is used in refractory pediatric rheumatic diseases (PRD). Data regarding the effects of RTX on the immune system in children and safety…Abstract Number: 2940 • 2015 ACR/ARHP Annual Meeting
Risk Factors for Late-Onset Thrombosis in Systemic Lupus Erythematosus (SLE)
Background/Purpose: Thrombotic events (TE) cause great morbidity and mortality in SLE patients. Studies of TE in SLE focus on early-onset TE. While the incidence of…Abstract Number: 166 • 2014 ACR/ARHP Annual Meeting
Risk Factors for Gout Attack Recurrence during Urate-Lowering Allopurinol Treatment
Background/Purpose Gout is a recurrent inflammatory arthritis caused by crystal deposition of monosodium urate, which can be prevented urate-lowering agents such as allopurinol. However, gout…Abstract Number: 7 • 2013 ACR/ARHP Annual Meeting
Prospective Validation Of The Global Antiphospholipid Syndrome Score (GAPSS)
Prospective Validation of the Global Antiphospholipid Syndrome Score (GAPSS) Background/Purpose: Backgrounds: This study was performed to prospectively and independently validate the GAPSS (1) (Global APS…Abstract Number: 631 • 2012 ACR/ARHP Annual Meeting
Peripheral Neuropathy Due to Systemic Lupus Erythematosus (SLE) Itself: Incidence, Disease Risk Factors and Outcome
Background/Purpose: Peripheral neuropathy (PN) solely attributable to SLE itself is difficult to define since most of these patients are exposed to several other conditions that…Abstract Number: 605 • 2012 ACR/ARHP Annual Meeting
Increased Incidence of Herpes Zoster Among Patients with Systemic Lupus Erythematosus
Background/Purpose: Herpes zoster (HZ) is the painful reactivation of latent varicella zoster virus infection. The incidence of HZ may be increased in some autoimmune…
- « Previous Page
- 1
- …
- 10
- 11
- 12